Clinical and economic evaluation of exenatide for formulary decisions

Abstract

This study was designed to provide an assessment for healthcare organisations to make formulary decisions on Byetta®* (exenatide). The drug was shown to be efficacious in treating type 2 diabetes mellitus when used as adjunctive therapy with other oral antidiabetic drugs. The Centre for Outcomes Research Diabetes Model analyses suggested that the drug treatment fails to achieve a threshold level of the incremental cost-effectiveness ratio until 50 years have passed. Sensitivity analyses suggested that maintaining an appropriate haemoglobin A1c level is essential for the treatment to be cost effective. A budget impact analysis with a hypothetical plan produced a 2.1 cent base case compliance-adjusted, per member per month cost in Year 1. One-way sensitivity analyses indicated that the two major determinants are compliance and the percentage of individuals expected to be on exenatide. The author's conclude that further research is needed to include exenatide for the formulary decision. © 2007 Informa UK Ltd.